Navigation Links
Blue Cross and Blue Shield of Oklahoma Launches an Integrated Medical-Dental Health Program
Date:4/9/2008

TULSA, Okla., April 9 /PRNewswire-USNewswire/ -- Blue Cross and Blue Shield of Oklahoma is announcing the launch of BlueCare Dental Connection(SM), a new integrated medical-dental program. The program is unique in the industry because it compares an individual's medical and dental data to create a customized plan aimed to improve their health. This new approach is designed to specifically help users optimize their overall health by making better decisions about their oral health through the pursuit of evidence-based research and information.

Research continues to show a potential link between oral care and overall health. Through BlueCare Dental Connection, Blue Cross and Blue Shield can utilize medical and dental claim information to identify members at risk with health conditions complicated by dental disease, such as diabetes, cardiovascular disease and pregnancy. By analyzing this claim data, the Oklahoma insurer hopes to proactively reach out to these members and influence their behavior before any adverse conditions escalate further. In addition, Blue Cross and Blue Shield is reaching out to select members determined to be at risk for dental caries or periodontal (gum) disease in an effort to minimize or prevent these dental conditions early. The goal of the BlueCare Dental Connection program, which is available at no cost to members who carry Blue Cross and Blue Shield of Oklahoma medical and dental insurance, is to help members identify potential opportunities for dental health intervention and prevention and realize the benefits to their overall health.

Targeted intervention to these at-risk members will be accomplished through a coordinated effort of mailings and staff outreach in addition to expanded Web tools and information on the Blue Cross and Blue Shield of Oklahoma Web site at http://www.bcbsok.com.

"We feel this program is both critical in maintaining our members' o
'/>"/>

SOURCE Blue Cross Blue Shield of Oklahoma
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Anthem Blue Cross Tackles Childhood Obesity in California Through Free BMI Workshops for Pediatric and Family Medicine Health Care Providers
2. Business Leader, Nonprofit Volunteer to Head the American Red Cross
3. Researchers Able to Continue their Work to Help Patients Thanks to McDevitt Excellence in Research Awards from Blue Cross Blue Shield of Michigan Foundation
4. Daniel Corcoran named President of Anthem Blue Cross and Blue Shield in Maine
5. Partnership for Prescription Assistance Celebrates Three Year Anniversary; Helps Nearly 5 Million Uninsured Patients Across United States
6. Blue Cross Stop-Smoking Program Achieves All-Time High Quit Rate
7. NCQA Awards Quality Plus Distinction to Blue Cross and Blue Shield of Minnesota for Physician and Hospital Quality Measures
8. Anthem Blue Cross Announces Initiative Aimed at Preventing Serious Medical Errors; Company Committed to Protecting Members Health and Finances by Not Reimbursing Major Preventable Adverse Events
9. Empire Blue Cross Blue Shield Announces Initiative to Protect Members Health Aimed at Preventing Serious Medical Errors
10. Anthem Blue Cross and Blue Shield in Wisconsin Announces Initiative Aimed at Preventing Serious Medical Errors; Company Committed to Protecting Members Health and Finances by Not Reimbursing Major Preventable Adverse Events
11. In Face of Continuing Katrina and Rita Needs Red Cross Adds Resources to Gulf Coast
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10GeoVax Labs Inc Celebrates 21st World AIDS Day With Continued Clinical Trial Progress 15013 1GeoVax Labs Inc Celebrates 21st World AIDS Day With Continued Clinical Trial Progress 15013 2GeoVax Labs Inc Celebrates 21st World AIDS Day With Continued Clinical Trial Progress 15013 3GeoVax Labs Inc Celebrates 21st World AIDS Day With Continued Clinical Trial Progress 15013 4GeoVax Labs Inc Celebrates 21st World AIDS Day With Continued Clinical Trial Progress 15013 5GeoVax Labs Inc Celebrates 21st World AIDS Day With Continued Clinical Trial Progress 15013 6nContact Announces Initiation of Clinical Trials for the Treatment of Paroxysmal Atrial Fibrillation Utilizing New Convergent Ablation Procedure 6632 1nContact Announces Initiation of Clinical Trials for the Treatment of Paroxysmal Atrial Fibrillation Utilizing New Convergent Ablation Procedure 6632 2MedQuist Integrates Search Engine from Primordial with SpeechQ 28TM 29 for Radiology 6630 1MedQuist Integrates Search Engine from Primordial with SpeechQ 28TM 29 for Radiology 6630 2